Study to investigate interaction between carbamazepine & CNV1014802

• Research type

  Research Study

• Full title

  Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between Carbamazepine and CNV1014802 in Healthy Subjects

• IRAS ID

  181606

• Contact name

  Joanne Palmer

• Contact email

  joanne.palmer@convergencepharma.com

• Sponsor organisation

  Convergence Pharmaceuticals Ltd

• Eudract number

  2015-001926-41

• Duration of Study in the UK

  0 years, 1 months, 27 days

• Research summary

  The Sponsor is developing the study drug, CNV1014802, for the potential treatment of trigeminal neuralgia (TN), a neuropathic (nerve) disorder which causes sudden, severe facial pain. The study drug also has the potential to treat other neuropathic disorders.

  This study will try to identify how the study drug interacts with another drug, carbemazepine, currently used for the treatment of TN.

• REC name

  Wales REC 1

• REC reference

  15/WA/0183

• Date of REC Opinion

  18 Jun 2015

• REC opinion

  Further Information Favourable Opinion